New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
The new site enables end-to-end production of viral vector gene therapies
Upgrades 2025 full-year CDMO sales and margin outlook
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Subscribe To Our Newsletter & Stay Updated
